Regulus Therapeutics Inc. (RGLS)
Jun 25, 2025 - RGLS was delisted (reason: acquired by Novartis)
8.16
+0.02 (0.25%)
Inactive · Last trade price
on Jun 24, 2025
Company Description
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases.
The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease.
It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
Regulus Therapeutics Inc. was formerly known as Regulus Therapeutics LLC and changed its name to Regulus Therapeutics Inc. in January 2009.
The company was incorporated in 2007 and is based in San Diego, California. As of June 25, 2025, Regulus Therapeutics Inc. operates as a subsidiary of Novartis AG.
Regulus Therapeutics Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Oct 4, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Joseph Hagan |
Contact Details
Address: 4224 Campus Point Court, Suite 210 San Diego, California 92121 United States | |
| Phone | 858 202 6300 |
| Website | regulusrx.com |
Stock Details
| Ticker Symbol | RGLS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001505512 |
| CUSIP Number | 75915K309 |
| ISIN Number | US75915K3095 |
| Employer ID | 26-4738379 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph P. Hagan M.B.A. | Chief Executive Officer and Director |
| Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research and Development and Director |
| Crispina Calsada CPA | Chief Financial Officer |
| Daniel J. Penksa | Vice President of Finance and Controller |
| Christopher Ray Aker J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations |
| Dr. Rekha Garg M.D., M.S. | Chief Medical Officer |
| Edmund Lee Ph.D. | Vice President of Translational Medicine |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jun 25, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jun 25, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jun 25, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jun 25, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jun 25, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jun 25, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jun 25, 2025 | POS AM | Post-Effective amendments for registration statement |
| Jun 25, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 25, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |